Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- In ATTR-CM, imaging works best as a coordinated pathway, not a collection of studies.
- No single tool replaces phenotype, monoclonal-protein exclusion, and clinical context.
- Integration and appropriate sequencing of diagnostic modalities are more important than performing additional investigations.
What an ATTR-CM Imaging Workup Should Accomplish
An ATTR-CM imaging workup is most effective when performed as part of a structured diagnostic pathway rather than as a series of isolated investigations. Echocardiography raises suspicion, cardiac magnetic resonance imaging (MRI) adds tissue-level and structural context, and bone-avid scintigraphy can support noninvasive confirmation, but none of them carries the whole diagnosis safely by itself. When used sequentially and interpreted together, these modalities provide complementary information that supports an accurate diagnosis.
What Each Major Tool Contributes Uniquely
Each imaging modality provides distinct but complementary diagnostic information. Echocardiography identifies structural and functional abnormalities, cardiac MRI provides tissue characterization, and bone-avid scintigraphy supports a noninvasive diagnosis when monoclonal protein disorders have been excluded. Interpretation of bone-avid scintigraphy findings should always be considered in the context of the patient's clinical presentation and the results of monoclonal protein testing rather than in isolation.
Why a Coordinated Diagnostic Approach Improves Diagnostic Accuracy
A coordinated diagnostic approach is preferable to performing multiple investigations without a clear diagnostic strategy. Each diagnostic modality should be interpreted within the context of the patient's clinical phenotype, monoclonal protein evaluation, and overall clinical assessment. Diagnostic accuracy is enhanced by the appropriate sequencing and integration of complementary investigations rather than by performing additional isolated studies. This structured approach is consistent with current guideline recommendations, which emphasize confirming the diagnosis of ATTR-CM before initiating disease-specific therapy in accordance with the approved indication.
Practical Sequencing Checklist
Before requesting additional studies, consider the following:
- Is the investigation clinically indicated, or is it unlikely to provide additional diagnostic information?
- Has monoclonal protein testing been done so a positive scan can be interpreted correctly?
- Will the next study change the decision, or just add a finding that still needs context?
- Are results being read together as a sequence rather than in isolation?
Clinical Decision Point
The relevant clinical question is not which individual test is superior, but whether investigations are being applied in a coordinated sequence that enables a reliable diagnosis. A positive bone-avid scan only indicates ATTR-CM once monoclonal disease is excluded and the phenotype fits. Performing additional investigations without a structured diagnostic approach may increase the amount of information available without improving diagnostic certainty.
Frequently Asked Questions
Is one imaging test enough to diagnose ATTR-CM?
No. Echocardiography, cardiac MRI, and bone-avid scintigraphy each answer part of the question, but a confident diagnosis depends on combining them with phenotype and monoclonal-protein testing.
Why does monoclonal-protein testing accompany imaging?
Monoclonal protein testing accompanies imaging because a positive bone-avid scan can be misleading if monoclonal disease hasn't been addressed. Excluding it allows for a positive scan be interpreted as ATTR rather than another amyloid type.
Why is a coordinated imaging pathway preferred?
Diagnostic accuracy is improved by the appropriate sequencing and integration of complementary investigations rather than by performing multiple studies in isolation. Additional testing cannot substitute for a structured diagnostic pathway.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Confirm the Diagnosis
- Screening and Early Detection in ATTR-CM
- 99mTc-PYP Scintigraphy and Diagnostic Workup
- Differential Diagnosis in ATTR-CM
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Interpretation and Reporting of Cardiac Scintigraphy with Bone-Avid Tracers in Suspected Transthyretin Cardiac Amyloidosis (ATTR-CA). American Society of Nuclear Cardiology
- Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions. Trends in Cardiovascular Medicine
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.